The document discusses how pharmaceutical companies can manage online adverse events. It outlines a process for monitoring social media and other online sources to detect adverse event mentions related to a company's products. Key aspects of the proposed process include setting up global and local monitoring teams, using a tool like Radarly to capture mentions, qualifying posts according to a response grid, and reporting any potential adverse events to pharmacovigilance teams within 24 hours. The goal is to have a structured yet adaptable process that allows companies to monitor online conversations and respond appropriately to any safety issues.
2. About this presentation
Why using social media listening and
monitoring to impact Esmya速 digital
strategy?
How to structure as a global
pharmaceutical company to handle
social media mentions?
How to setup a robust social media
process both at a global and local
scale?
How to handle online adverse events
as an international team?
Online monitoring process | Haider Alleg
2
Munich (06.02.2013)
3. About Gedeon Richter
and Esmya速
Development of generic drugs and chemical processes as well
A Pan-European specialty pharmaceutical company
as biotechnology
A 112 year old company present in more than thirty countries An expanding product portfolio
Online monitoring process | Haider Alleg
3
Munich (06.02.2013)
4. About Gedeon Richter
and Esmya速
Online monitoring process | Haider Alleg
4
Munich (06.02.2013)
5. About me
Gedeon Richter Global eMarketing Manager
(Geneva)
27 years old, 10 years working in the digital industry
2 master degrees: International Marketing and Business /*Digital worker since 2003*/
Administration
5 years in the healthcare industry and global projects (Novartis,
Roche, Pfizer, NovoNordisk, Medtronic...)
e-insights mining, social media campaigns, performance
campaigns, metrics and dash-boarding...
Online monitoring process | Haider Alleg
5
Munich (06.02.2013)
6. Context
Esmya速
launched in
Europe since
2012
(present in UK, DE and some CEE
countries, others to follow soon)
Online monitoring process | Haider Alleg
6
Munich (06.02.2013)
7. Context
Esmya速 digital strategy is a core DNA branch
of the brand plan
Measuring Esmya@ brand impact on corporate image
(Biotech drug vs. Generics)
Engaging with doctors (gynecologists, surgeons and
pathologists)
Help patients put a name on a condition (disease
awareness strategy)
Online monitoring process | Haider Alleg
7
Munich (06.02.2013)
8. Context
Gedeon Richter (GR) is structuring
digital activities globally and locally
Listening to know where to act and
which content strategy to adopt
Defining a process globally and
improve our efficiency locally
Engage in social media from a
corporate, patients and doctors angle
Online monitoring process | Haider Alleg
8
Munich (06.02.2013)
9. Listening to diagnostic
and build the e-strategy
E-insights mining (qualitative) E-monitoring (quantitative)
Online monitoring process | Haider Alleg
9
Munich (06.02.2013)
10. Step 1. Take a snapshot
Online monitoring process | Haider Alleg
10
Munich (06.02.2013)
11. Listening to diagnostic
and build the e-strategy
2 pilot studies in German and English, with focus in
the UK and Germany
2 months of research, humanized approach (native
speakers)
Verbatim based on the disease keywords, Esmya速
and Gedeon Richter mentions
Online monitoring process | Haider Alleg
11
Munich (06.02.2013)
12. Listening to diagnostic
and build the e-strategy
Objectives of the study: a fly on the wall
Who is speaking? Profile of talkers.
Where are nodes of communication around
the product, the disease?
Where are KOLs?
What is the reputation of the drug? The lab?
Among patients? Among doctors?
What are the topics? Why?
How to engage with them?
Where are potential adverse events?
Online monitoring process | Haider Alleg
12
Munich (06.02.2013)
13. Listening to diagnostic
and build the e-strategy
Online monitoring process | Haider Alleg
13
Munich (06.02.2013)
14. Listening to diagnostic
and build the e-strategy
Online monitoring process | Haider Alleg
14
Munich (06.02.2013)
15. Step 2. Establish the digital strategy
Online monitoring process | Haider Alleg
15
Munich (06.02.2013)
16. Key takeaways for
Esmya速 digital strategy
Online monitoring process | Haider Alleg
16
Munich (06.02.2013)
17. Step 3. Take the pulse
Online monitoring process | Haider Alleg
17
Munich (06.02.2013)
18. Monitoring tools market
Existing solutions are
either:
Not easy to setup
Not easy to scale
Not easy to use
Not cheap!
Too technical
Not adapted
Online monitoring process | Haider Alleg
18
Munich (06.02.2013)
20. Setup the monitoring to
answer business goals
We setup Radarly at a global
level to measure in all markets:
Brand mentions
Event impact
Marketing campaigns impact
Uterine fibroids discussions
KOLs exposure
Adverse events
Scientific publications
Online monitoring process | Haider Alleg
20
Munich (06.02.2013)
22. Setup the monitoring to
answer business goals
Medical/ ≒Prepare the
verbatim
marketing
PV/ ≒Review and
training updates
Regulatory
≒Implementation
of English
eMarketing (global)
verbatim
Local ≒Adapt global
Medical/ verbatim to local
market
Marketing
Local PV/ ≒Review local
verbatim
Regulatory
Online monitoring process | Haider Alleg
22
Munich (06.02.2013)
23. Monitoring process structure:
Think global, act local
Radarly captures
mentions in the global
dashboard
y
da
AU
n/
TO
mi
20
Local native speakers Global eMarketer
qualify the posts in 1h / day assigned posts to local
English (Marketer/PV) native speakers
Online monitoring process | Haider Alleg
23
Munich (06.02.2013)
24. Monitoring process structure:
Think global, act local
Decentralised
Clustered
Centralised at the HQ
Online monitoring process | Haider Alleg
24
Munich (06.02.2013)
25. Monitoring process
stakeholders
RH
Innovation Marketing
Corporate
Events Coms
Key stakeholders Digital Social PR
media
are required for monitoring
success Legal
process IT
Sales PV
Med
Marketing Regulatory
Med Info
Online monitoring process | Haider Alleg
25
Munich (06.02.2013)
26. Monitoring tool box:
Response grid and criticality matrix
Online Monitoring
One to one One to Many
Criticality Response Contact
KOLs list
matrix grid plan
Online monitoring process | Haider Alleg
26
Munich (06.02.2013)
27. Monitoring tool box:
Response grid and criticality matrix
3 levels of content interactions
White, green, red list content, where
designed employee and external agency
can answer based on a list of predefined
answers
Grey list, updated as soon as a new
topic, question pops up on a social media
support by experts
Black list, where the DEFCON mode
may be activated with a proactive and
protective answer.
Online monitoring process | Haider Alleg
27
Munich (06.02.2013)
28. Monitoring tool box:
Response grid and criticality matrix
Online monitoring process | Haider Alleg
28
Munich (06.02.2013)
29. Monitoring tool box:
Response grid and criticality matrix
Criticality =
Detectability X Severity X Frequency
Monitoring and qualifying posts in
Radarly help us track a common KPI and
to take quick decisions
Online monitoring process | Haider Alleg
29
Munich (06.02.2013)
30. Monitoring tool box:
Response grid and criticality matrix
Response grid
Each posts collected and
qualified (White, Green, Red...) is
associated with a pre-defined
action or message in a database
updated globally.
Helps keep a unique voice and
tonality.
Anticipate and solve potential
crisis with the crisis committee.
Online monitoring process | Haider Alleg
30
Munich (06.02.2013)
32. Definition of an adverse
event reaction
Adverse Event (or Adverse Experience)
Any untoward medical occurrence in a patient
or clinical investigation subject administered a
pharmaceutical product and which does not
necessarily have to have a causal relationship
with this treatment.
An adverse event (AE) can therefore be any
unfavorable and unintended sign (including an
abnormal laboratory finding, for example),
symptom, or disease temporally associated
with the use of a medicinal product, whether or
not considered related to the medicinal
product.
Source: http://www.emea.europa.eu/docs/en_GB/document_library/Scienti鍖c_guideline/2009/09/WC500002749.pdf
Online monitoring process | Haider Alleg
32
Munich (06.02.2013)
33. Obligations as
a pharma player
New Guideline on good pharmacovigilance practices published on 2nd July 2012
Two scenarios:
1. Digital media company sponsored.
2. Digital media not company sponsored.
How is defined company sponsored?
if it is owned, paid for and/or controlled by the Market Authorization Holder
Note: a donation (financial or otherwise) to an organization/site by a Market Authorization Holder does not
constitute ownership, provided that the MAH does not control the final content of the site.
Source: Internal PV
Online monitoring process | Haider Alleg
33
Munich (06.02.2013)
34. How to react vs.
an adverse event?
1. The adverse event is collected by Radarly
2. A team member is qualifying it under the potential
AE category on a defined time screening (e.g. 10
minutes every day)
3. An email is sent within 24h to local PV if one or
multiple AEs are detected during the screening
4. PV asses if this is an actual AE (association with
the drug, drug potential side effects, possibility of
contacting the patient...)
5. If the AEs is valid, PV is reporting it as any other
AEs coming from other channel.
Source: ABPI - UK
Online monitoring process | Haider Alleg
34
Munich (06.02.2013)
35. Next steps for Gedeon Richter
Follow and adjust Esmya速 digital
plan for 2013-15
Continue the integration of new
brand teams and countries in the
global monitoring activity
Continue training more and more
colleagues locally to expand our
capability of absorbing mentions
qualification
Online monitoring process | Haider Alleg
35
Munich (06.02.2013)
38. Obligations as
a pharma player
Digital media company sponsored
The company should regularly screen it for potential reports of suspected adverse reactions.
Frequency of the screening should allow for potential valid cases to be reported on time to the Authorities
based on the date the information was posted on the media: At a minimum, regular screening every two/
three days.
Clear process should be in place to report this case (valid or non-valid) to the local PV Officer within 24
hours.
Obligation to screen for adverse reactions and any cases of lack of efficacy, misuse, overdose, abuse, off-
label use, pregnancy, breastfeeding
Source: Internal PV
Online monitoring process | Haider Alleg
38
Munich (06.02.2013)
39. Obligations as
a pharma player
Digital media non company sponsored (ex: forum)
If the company becomes aware of a report of suspected adverse reaction, it should be assessed and
handled as a spontaneous report.
Day 0 is not the day of posting but the day one Gedeon Richter employee becomes aware of the report.
No regular screening is requested.
Clear process should be in place to report this case (valid or non-valid) to the local PV Officer within 24
hours.
No obligation to screen for adverse reactions and any cases of lack of efficacy, misuse, overdose, abuse,
off-label use, pregnancy, breastfeeding
Source: Internal PV
Online monitoring process | Haider Alleg
39
Munich (06.02.2013)
40. Crisis Process
Core task force prepared
in case (PR, IT, Legal,
Marketing...)
Quick response on
situations even locally
(same platform)
Anticipate by learning
before acting online
Avoid crisis by adapting
the right messages to the
right audience through
the right channel
Online monitoring process | Haider Alleg
40
Munich (06.02.2013)
41. Agenda
10. Monitoring process structure: Think global, act
1. About this presentation local
2. About Gedeon Richter and Esmya速 11. Monitoring process stakeholders
3. About me 12. Monitoring tool box: Response grid and criticality
matrix
4. Context
13. Crisis process
5. Listening to diagnostic and build e-strategy
14. Definition of an adverse event reaction
6. Why listening using insights mining?
15. Obligations as a pharma player
7. Key takeaways for Esmya速 digital strategy
16. How to react vs. an adverse event?
8. Monitoring tools market
17. Next steps for Gedeon Richter
9. Setup the monitoring to answer business goals
18. Questions
Online monitoring process | Haider Alleg
41
Munich (06.02.2013)